Size-dependent interactions between calciprotein particles and vascular endothelium

钙蛋白颗粒与血管内皮细胞之间大小依赖性的相互作用

阅读:1

Abstract

The underlying mechanisms governing the interactions between nanoparticles and vascular endothelial barrier remain largely unexplored, which is crucial for the optimal design of nanoparticles for clinical applications. In this study, the size-dependent interactions between calciprotein particles (CPPs) and endothelial cells (ECs) were investigated using a rat model of chronic kidney disease (CKD) induced by 5/6 nephrectomy. Two primary types of CPP1 were studied: small-sized CPP1 (S-CPP1, <50 nm) and larger CPP1 (L-CPP1, <100 nm), detected three and five weeks post-surgery, respectively. By adjusting the amounts of Ca(2+), HPO(4) (2-) and H(2)PO(4) (-) ions in Dulbecco's Modified Eagle Medium supplemented with 10 % (V/V) fetal bovine serum and 1 % (V/V) Pen-Strep solution, S-CPP1 (<50 nm) with an elliptical shape, L-CPP1 (50-100 nm), and secondary CPPs (CPP2, >100 nm) with a needle-like crystalline structure, resembling endogenous CPPs, were synthesized. The results showed that S-CPP1 significantly increased endothelial permeability at concentrations of 445 μg/mL and 890 μg/mL, thereby disrupting the integrity of the endothelial barrier formed by a confluent monolayer of ECs. Immunofluorescence analysis revealed that L-CPP1 was internalized by ECs via endocytosis, while S-CPP1 disrupted VE-cadherin junctions, leading to irregular cell morphology and widened intercellular gaps. These structural changes likely contribute to medial calcification as CPPs accumulate within the circulatory system. In conclusion, the findings underscore that the interaction between CPPs and the vascular endothelium is strongly size-dependent, with significant implications for vascular system health and the design of nanoparticle-based therapies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。